Bristol Myers Ends Clinical Development of ORM-6151

Company Orum Therapeutics / Bristol Myers Squibb Event Type Program Discontinuation Modality Degrader-Antibody Conjugate Asset ORM-6151 (BMS-986497) Target CD33-Directed Delivery of a GSPT1 Molecular-Glue Degrader Disease Area Acute Myeloid Leukemia and Myelodysplastic Syndrome Summary Bristol Myers Squibb discontinued the Phase I program for ORM-6151, also…